Singulair Montelukast Sodium

The information on this site is intended for health care professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Go to AR HCP Site
Allergy HCP
Prescribing Information Patient Information Selected Safety Information Return to singulair.com

How to administer SINGULAIR oral granules to appropriate pediatric patients

SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older.

SELECTED SAFETY INFORMATION

  • SINGULAIR is contraindicated in patients with hypersensitivity to any component of this product.
  • Safety and effectiveness of SINGULAIR in patients younger than 12 months with asthma have not been established.

SELECTED SAFETY INFORMATION continued below

1 Open
2 Pour
3 Feed

OPEN the packet of SINGULAIR 4-mg oral granules.

  • Do not open the packet until you are ready to give SINGULAIR 4-mg oral granules to the patient.
  • Contents of 1 packet=1 dose.
Oral Granules

For more details on the timing of dosing, please read the Dosage and Administration section of the
Prescribing Information.

SELECTED SAFETY INFORMATION (continued)

  • SINGULAIR should not be used as rescue medication to treat acute asthma attacks. Patients should be advised to have appropriate rescue medication available.
  • While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, SINGULAIR should not be abruptly substituted for inhaled or oral corticosteroids.
  • Patients receiving SINGULAIR should not decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.

Please see Selected Safety Information about SINGULAIR.

Before prescribing SINGULAIR, please read the Prescribing Information.

See all references.

RESP-1007091-0003 01/12

For general information and other services for physicians

Merck Services Merck OnCall